EyePoint Pharmaceuticals (NASDAQ: EYPT), is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products.

 

On May 8th, the company announced financial results for its fiscal 2018 third quarter and nine months ended March 31, 2018 and provided a company update. As per management, the acquisition of Icon Bioscience, Inc. and its FDA approved product, DEXYCU™, has significantly increased EyePoint Pharmaceuticals’ revenue potential and accelerates its planned transformation to a sustainable growth company.

 

The combination of experienced executives leading company’ commercial team and the additional capital from EW Healthcare and SWK positions EyePoint to successfully execute on the launch of two new products in the first half of 2019, pending favorable regulatory review of YUTIQ™. Additionally, the company anticipates the annual revenue potential for DEXYCU to be $150 – $200 million by the end of the third year on the market.

 

So far liquidity and financial flexibility is concerned, the Company had cash and cash equivalents totaling $16.3 million at March 31, 2018, and, subject to stockholder approval at a special meeting of shareholders scheduled for June 22, 2018, has capital commitments of an additional $30.5 million from EW Healthcare, a third-party investor, and SWK.

 

Therefore, the Company is currently projecting a cash balance of approximately $38.0 million at June 30, 2018, the end of its current fiscal year. The Company expects these proceeds will provide the financial resources to commence the launch of DEXYCU and YUTIQ.

 

Near-Term Goals and Upcoming Milestones:

• Gain approval of the second tranche investment by EW Healthcare at the June 22, 2018, special meeting of stockholders.
• Implement the Company’s four-pillar commercialization plan:
  • Complete the build out of the sales organization;
  • Implement the marketing plan;
  • Continue to progress market access programs; and
  • Initiate medical education initiatives.
• Secure pass-through reimbursement for DEXYCU.
• Receive FDA approval for YUTIQ based on the PDUFA action date of November 5, 2018. Present data at leading medical congresses, including for YUTIQ at the American Society of Retina Specialists (ASRS) annual meeting being held in Vancouver from July 20-25.
• Launch DEXYCU and YUTIQ (subject to FDA approval) in the first half of calendar 2019.

 

Analyst tracking the stock believes that the launch of DEXYCU plus the potential approval of YUTIQ will position EYPT to launch two products in the first half of 2019 and significantly leverage the commercial organization it is building. Moreover, the company continues to present positive date on YUTIQ, as recently two weeks ago at the Association for Research in Vision and Ophthalmology or ARVO’s annual meeting.

 

To summarise, this is a very exciting time for EyePoint Pharmaceuticals as the company continues to make excellent progress, executing on its business plan, including preparations for commercialization of DEXYCU and YUTIQ in the U.S. in the first half of 2019. Most Importantly, the company is well capitalized, assuming a favorable shareholder vote on June 22, with the resources necessary to successfully launch DEXYCU and YUTIQ. Several brokerage firms have initiated coverage on the company, and the stock currently has an average rating of “Buy”.

 

About the Company:  EYPT, headquartered in Watertown, MA, is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with a high unmet medical need to help improve the lives of patients with serious eye disorders.

 

Product Pipeline: EyePoint has developed three FDA-approved products utilizing its proprietary DurasertTM Technology. The company is utilizing its Durasert bioerodible technology platform in collaboration with other pharmaceutical companies to develop new sustained-release products to treat retinal diseases and other ocular conditions.

 

Key Recent Accomplishments:

• Acquired privately-held Icon Bioscience, Inc. and its FDA approved product, DEXYCU™.
• DEXYCU was approved by the FDA on February 9, 2018, for the treatment of postoperative inflammation and is administered as a single intraocular injection at the end of surgery.
• EyePoint has expanded the DEXYCU global IP portfolio with Notices of Allowance for two additional patents, including potential claims relating to a method of treating inflammation of an eye following cataract surgery by delivering extremely small (4-6µL) amounts of dexamethasone in acetyl triethyl citrate. These two additional patents, once allowed, will extend to 2032 and 2034.
• A New Drug Application (NDA) for YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg three-year treatment for noninfectious posterior segment uveitis was submitted to the Food and Drug Administration (FDA) in January and was accepted for filing in March with a November 5, 2018 PDUFA date.
• EyePoint has enhanced the healthcare and capital markets expertise of the Board of Directors with the appointment of Ron Eastman, a Managing Director at EW Healthcare Partners with over 40 years of experience in building healthcare companies.
• EyePoint has hired experienced executives to lead the Company’s commercial team and to ensure successful execution of the launches of DEXYCU and YUTIQ
  EyePoint presented data on YUTIQ at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting.
• EyePoint delisted from the Australian Securities Exchange effective as of May 7, 2018

 

 

Fiscal Third Quarter Results

Revenue: Revenue for the third fiscal quarter ended March 31, 2018, totaled $928,000 compared to $590,000 for the prior-year quarter.  Revenues in both periods were derived from feasibility study agreements and royalty income.

 

Expenses: Operating expenses for the three months ended March 31, 2018, decreased slightly to $5.6 million from $5.8 million a year earlier, due primarily to lower clinical trial costs and stock-based compensation expense, partially offset by higher regulatory and clinical consulting services in support of YUTIQ and higher personnel and related expenses.

 

Profitability: Net loss for the quarter ended March 31, 2018, was $7.0 million, or $0.15per share, compared to a net loss of $5.1 million, or $0.15 per share, for the prior-year quarter.

 

Liquidity and financial flexibility: At March 31, 2018, cash and cash equivalents totaled $16.3 million, a total number of common shares outstanding at March 31, was $53.9 million. During the third quarter, net cash used from operations totaled approximately $4.8 million compared to $5 million in the second fiscal quarter.

The company currently anticipate net cash used from operations to range between $6.5 million to $7.5 million in its fiscal fourth quarter as it advances towards the commercial readiness for the launch of DEXYCU and if approved by the FDA YUTIQ.

 

Key risk factors:

• Successful completion of the upcoming milestones would lead future direction for the company. Any adversities related to these forthcoming milestones might adversely impact the overall investor sentiments.
• EYPT is still an early stage entity and has not yet generated revenue and will likely operate at a loss as it grows its market position and seeks ways to monetize it. The company’ prospects are significantly dependent on DEXYCU and YUTIQ, which might have limited sales potential initially.
• EYPT has a history of operating losses. Therefore, any time or cost overrun in its ongoing R&D activities and its impact on business & financial profile will remain a key business sensitivity factor.

 

Stock Chart:

Comments:

• On Friday, June 22th, 2018, EYPT closed at $2.00, on an average volume of 182K shares exchanging hands. Market capitalization is $108 million. Current RSI is 44.83
• In the past 52 weeks, shares of EYPT have traded as low as $0.93 and as high as $2.88.
• At $2.00, shares of EYPT are trading below its 50-day moving average (MA) at $2.10 and above its 200 days moving average at $1.41

 

 

Disclaimer

Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.

Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.

This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.

We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.

When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.

17B Disclosure

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.

TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.

Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.